Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Original article

Vol. 150 No. 2324 (2020)

Multidisciplinary care in amyotrophic lateral sclerosis: a 4-year longitudinal observational study

DOI
https://doi.org/10.4414/smw.2020.20258
Cite this as:
Swiss Med Wkly. 2020;150:w20258
Published
09.06.2020

Summary

References

  1. Rooney J, Byrne S, Heverin M, Corr B, Elamin M, Staines A, et al. Survival analysis of irish amyotrophic lateral sclerosis patients diagnosed from 1995-2010. PLoS One. 2013;8(9):e74733. doi:.https://doi.org/10.1371/journal.pone.0074733
  2. Kaufmann P, Levy G, Thompson JL, Delbene ML, Battista V, Gordon PH, et al. The ALSFRSr predicts survival time in an ALS clinic population. Neurology. 2005;64(1):38–43. doi:.https://doi.org/10.1212/01.WNL.0000148648.38313.64
  3. Zoccolella S, Beghi E, Palagano G, Fraddosio A, Guerra V, Samarelli V, et al.; SLAP Registry. Analysis of survival and prognostic factors in amyotrophic lateral sclerosis: a population based study. J Neurol Neurosurg Psychiatry. 2008;79(1):33–7. doi:.https://doi.org/10.1136/jnnp.2007.118018
  4. Pugliatti M, Parish LD, Cossu P, Leoni S, Ticca A, Saddi MV, et al. Amyotrophic lateral sclerosis in Sardinia, insular Italy, 1995-2009. J Neurol. 2013;260(2):572–9. doi:.https://doi.org/10.1007/s00415-012-6681-5
  5. Murphy M, Quinn S, Young J, Parkin P, Taylor B. Increasing incidence of ALS in Canterbury, New Zealand: a 22-year study. Neurology. 2008;71(23):1889–95. doi:.https://doi.org/10.1212/01.wnl.0000336653.65605.ac
  6. Robberecht W, Philips T. The changing scene of amyotrophic lateral sclerosis. Nat Rev Neurosci. 2013;14(4):248–64. doi:.https://doi.org/10.1038/nrn3430
  7. Brown RH, Al-Chalabi A. Amyotrophic Lateral Sclerosis. N Engl J Med. 2017;377(2):162–72. doi:.https://doi.org/10.1056/NEJMra1603471
  8. Niedermeyer S, Murn M, Choi PJ. Respiratory Failure in Amyotrophic Lateral Sclerosis. Chest. 2019;155(2):401–8. doi:.https://doi.org/10.1016/j.chest.2018.06.035
  9. Hobson EV, McDermott CJ. Supportive and symptomatic management of amyotrophic lateral sclerosis. Nat Rev Neurol. 2016;12(9):526–38. doi:.https://doi.org/10.1038/nrneurol.2016.111
  10. Chiò A, Logroscino G, Traynor BJ, Collins J, Simeone JC, Goldstein LA, et al. Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature. Neuroepidemiology. 2013;41(2):118–30. doi:.https://doi.org/10.1159/000351153
  11. Logroscino G, Traynor BJ, Hardiman O, Chiò A, Mitchell D, Swingler RJ, et al.; EURALS. Incidence of amyotrophic lateral sclerosis in Europe. J Neurol Neurosurg Psychiatry. 2010;81(4):385–90. doi:.https://doi.org/10.1136/jnnp.2009.183525
  12. Hinchcliffe M, Smith A. Riluzole: real-world evidence supports significant extension of median survival times in patients with amyotrophic lateral sclerosis. Degener Neurol Neuromuscul Dis. 2017;7:61–70. doi:.https://doi.org/10.2147/DNND.S135748
  13. Abe K, Aoki M, Tsuji S, Itoyama Y, Sobue G, Togo M, et al, Edaravone (MCI-186) ALS 19 Study Group. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16(7):505–12. doi:.https://doi.org/10.1016/S1474-4422(17)30115-1
  14. Van den Berg JP, Kalmijn S, Lindeman E, Veldink JH, de Visser M, Van der Graaff MM, et al. Multidisciplinary ALS care improves quality of life in patients with ALS. Neurology. 2005;65(8):1264–7. doi:.https://doi.org/10.1212/01.wnl.0000180717.29273.12
  15. Andersen PM, Abrahams S, Borasio GD, de Carvalho M, Chio A, Van Damme P, et al.; EFNS Task Force on Diagnosis and Management of Amyotrophic Lateral Sclerosis. EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)--revised report of an EFNS task force. Eur J Neurol. 2012;19(3):360–75. doi:.https://doi.org/10.1111/j.1468-1331.2011.03501.x
  16. Chiò A, Bottacchi E, Buffa C, Mutani R, Mora G ; PARALS. Positive effects of tertiary centres for amyotrophic lateral sclerosis on outcome and use of hospital facilities. J Neurol Neurosurg Psychiatry. 2006;77(8):948–50. doi:.https://doi.org/10.1136/jnnp.2005.083402
  17. Mayadev AS, Weiss MD, Distad BJ, Krivickas LS, Carter GT. The amyotrophic lateral sclerosis center: a model of multidisciplinary management. Phys Med Rehabil Clin N Am. 2008;19(3):619–31, xi. doi:.https://doi.org/10.1016/j.pmr.2008.04.004
  18. Traynor BJ, Alexander M, Corr B, Frost E, Hardiman O. Effect of a multidisciplinary amyotrophic lateral sclerosis (ALS) clinic on ALS survival: a population based study, 1996-2000. J Neurol Neurosurg Psychiatry. 2003;74(9):1258–61. doi:.https://doi.org/10.1136/jnnp.74.9.1258
  19. Ng L, Khan F. Multidisciplinary care for adults with amyotrophic lateral sclerosis or motor neuron disease. Cochrane Database Syst Rev. 2009;(4):CD007425. doi:.https://doi.org/10.1002/14651858.CD007425.pub2
  20. Rooney J, Byrne S, Heverin M, Tobin K, Dick A, Donaghy C, et al. A multidisciplinary clinic approach improves survival in ALS: a comparative study of ALS in Ireland and Northern Ireland. J Neurol Neurosurg Psychiatry. 2015;86(5):496–501. doi:.https://doi.org/10.1136/jnnp-2014-309601
  21. Marin B, Beghi E, Vial C, Bernard E, Lautrette G, Clavelou P, et al.; EURECALS consortium. Evaluation of the application of the European guidelines for the diagnosis and clinical care of amyotrophic lateral sclerosis (ALS) patients in six French ALS centres. Eur J Neurol. 2016;23(4):787–95. doi:.https://doi.org/10.1111/ene.12941
  22. Martin S, Trevor-Jones E, Khan S, Shaw K, Marchment D, Kulka A, et al. The benefit of evolving multidisciplinary care in ALS: a diagnostic cohort survival comparison. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(7-8):569–75. doi:.https://doi.org/10.1080/21678421.2017.1349151
  23. Bakker M, Creemers H, Schipper K, Beelen A, Grupstra H, Nollet F, et al. Need and value of case management in multidisciplinary ALS care: A qualitative study on the perspectives of patients, spousal caregivers and professionals. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(3-4):180–6. doi:.https://doi.org/10.3109/21678421.2014.971811
  24. O’Brien MR, Whitehead B, Jack BA, Mitchell JD. From symptom onset to a diagnosis of amyotrophic lateral sclerosis/motor neuron disease (ALS/MND): experiences of people with ALS/MND and family carers - a qualitative study. Amyotroph Lateral Scler. 2011;12(2):97–104. doi:.https://doi.org/10.3109/17482968.2010.546414
  25. Galvin M, Madden C, Maguire S, Heverin M, Vajda A, Staines A, et al. Patient journey to a specialist amyotrophic lateral sclerosis multidisciplinary clinic: an exploratory study. BMC Health Serv Res. 2015;15(1):571. doi:.https://doi.org/10.1186/s12913-015-1229-x
  26. Cheng HWB, Chan OMI, Chan CHR, Chan WH, Fung KS, Wong KY. End-of-life Characteristics and Palliative Care Provision for Patients With Motor Neuron Disease. Am J Hosp Palliat Care. 2018;35(6):847–51. doi:.https://doi.org/10.1177/1049909117735832
  27. Bede P, Oliver D, Stodart J, van den Berg L, Simmons Z, O Brannagáin D, et al. Palliative care in amyotrophic lateral sclerosis: a review of current international guidelines and initiatives. J Neurol Neurosurg Psychiatry. 2011;82(4):413–8. doi:.https://doi.org/10.1136/jnnp.2010.232637
  28. Pautex S, Janssens JP, Vuagnat H, Conne P, Zulian GB. Management of patients with amyotrophic lateral sclerosis. Swiss Med Wkly. 2005;135(41-42):626–9.
  29. Janssens JP, Adler D, Iancu Ferfoglia R, Poncet A, Genton Graf L, Leuchter I, et al. Assessing inspiratory muscle strength for early detection of respiratory failure in motor neuron disease: should we use MIP? SNIP or both? Respiration. 2019;98(2):114–24. doi:.https://doi.org/10.1159/000498972
  30. Brooks BR, Miller RG, Swash M, Munsat TL ; World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1(5):293–9. doi:.https://doi.org/10.1080/146608200300079536
  31. Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al.; BDNF ALS Study Group (Phase III). The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. J Neurol Sci. 1999;169(1-2):13–21. doi:.https://doi.org/10.1016/S0022-510X(99)00210-5
  32. Lépine JP, Godchau M, Brun P, Lempérière T. [Evaluation of anxiety and depression among patients hospitalized on an internal medicine service]. Ann Med Psychol (Paris). 1985;143(2):175–89.
  33. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361–70. doi:.https://doi.org/10.1111/j.1600-0447.1983.tb09716.x
  34. Perneger TV, Leplège A, Etter JF, Rougemont A. Validation of a French-language version of the MOS 36-Item Short Form Health Survey (SF-36) in young healthy adults. J Clin Epidemiol. 1995;48(8):1051–60. doi:.https://doi.org/10.1016/0895-4356(94)00227-H
  35. Ware J, Snow K, Kosinski M, Gandek B. SF-36 health survey: manual and interpretation guide. Boston, Massachusetts: The Health Institute, New England Medical Center; 1993.
  36. Kyle UG, Genton L, Karsegard L, Slosman DO, Pichard C. Single prediction equation for bioelectrical impedance analysis in adults aged 20--94 years. Nutrition. 2001;17(3):248–53. doi:.https://doi.org/10.1016/S0899-9007(00)00553-0
  37. Miller RG, Jackson CE, Kasarskis EJ, England JD, Forshew D, Johnston W, et al.; Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2009;73(15):1218–26. doi:.https://doi.org/10.1212/WNL.0b013e3181bc0141
  38. Rubin AD, Griffin GR, Hogikyan ND, Feldman EL. A new member of the multidisciplinary ALS team: the otolaryngologist. Amyotroph Lateral Scler. 2012;13(2):229–32. doi:.https://doi.org/10.3109/17482968.2011.643898
  39. Heritier Barras AC, Adler D, Iancu Ferfoglia R, Ricou B, Gasche Y, Leuchter I, et al., CeSLA group. Is tracheostomy still an option in amyotrophic lateral sclerosis? Reflections of a multidisciplinary work group. Swiss Med Wkly. 2013;143:w13830. doi:.https://doi.org/10.4414/smw.2013.13830
  40. Austin PC, Lee DS, Fine JP. Introduction to the Analysis of Survival Data in the Presence of Competing Risks. Circulation. 2016;133(6):601–9. doi:.https://doi.org/10.1161/CIRCULATIONAHA.115.017719
  41. Richard JL, Bouzourène K, Gallant S, Ricciardi P, Sudre P, Iten A, Burnand B. Validation et normes du SF-36 dans la population du canton de Vaud. Lausanne: Institut universitaire de médecine sociale et préventive, Raisons de santé, 28; 2000
  42. Pouget J. À propos des recommandations de diagnostic et de prise en charge dans les maladies neuromusculaires [About recommendations for diagnosis and management in neuromuscular diseases]. Rev Neurol (Paris). 2012;168(12):901. Article in French. doi:.https://doi.org/10.1016/j.neurol.2012.10.002
  43. Aridegbe T, Kandler R, Walters SJ, Walsh T, Shaw PJ, McDermott CJ. The natural history of motor neuron disease: assessing the impact of specialist care. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14(1):13–9. doi:.https://doi.org/10.3109/17482968.2012.690419
  44. Schellenberg KL, Hansen G. Patient perspectives on transitioning to amyotrophic lateral sclerosis multidisciplinary clinics. J Multidiscip Healthc. 2018;11:519–24. doi:.https://doi.org/10.2147/JMDH.S177563
  45. Mitchell JD, Callagher P, Gardham J, Mitchell C, Dixon M, Addison-Jones R, et al. Timelines in the diagnostic evaluation of people with suspected amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)--a 20-year review: can we do better? Amyotroph Lateral Scler. 2010;11(6):537–41. doi:.https://doi.org/10.3109/17482968.2010.495158
  46. Kano O, Iwamoto K, Ito H, Kawase Y, Cridebring D, Ikeda K, et al. Limb-onset amyotrophic lateral sclerosis patients visiting orthopedist show a longer time-to-diagnosis since symptom onset. BMC Neurol. 2013;13(1):19. doi:.https://doi.org/10.1186/1471-2377-13-19
  47. Paulukonis ST, Roberts EM, Valle JP, Collins NN, English PB, Kaye WE. Survival and Cause of Death among a Cohort of Confirmed Amyotrophic Lateral Sclerosis Cases. PLoS One. 2015;10(7):e0131965. doi:.https://doi.org/10.1371/journal.pone.0131965
  48. Hirose T, Kimura F, Tani H, Ota S, Tsukahara A, Sano E, et al. Clinical characteristics of long-term survival with noninvasive ventilation and factors affecting the transition to invasive ventilation in amyotrophic lateral sclerosis. Muscle Nerve. 2018;58(6):770–6. doi:.https://doi.org/10.1002/mus.26149
  49. Mandrioli J, Malerba SA, Beghi E, Fini N, Fasano A, Zucchi E, et al.; ERRALS Group. Riluzole and other prognostic factors in ALS: a population-based registry study in Italy. J Neurol. 2018;265(4):817–27. doi:.https://doi.org/10.1007/s00415-018-8778-y
  50. Calvo A, Moglia C, Lunetta C, Marinou K, Ticozzi N, Ferrante GD, et al. Factors predicting survival in ALS: a multicenter Italian study. J Neurol. 2017;264(1):54–63. doi:.https://doi.org/10.1007/s00415-016-8313-y
  51. Govaarts R, Beeldman E, Kampelmacher MJ, van Tol MJ, van den Berg LH, van der Kooi AJ, et al. The frontotemporal syndrome of ALS is associated with poor survival. J Neurol. 2016;263(12):2476–83. doi:.https://doi.org/10.1007/s00415-016-8290-1
  52. Yates E, Rafiq MK. Prognostic factors for survival in patients with amyotrophic lateral sclerosis: analysis of a multi-centre clinical trial. J Clin Neurosci. 2016;32:51–6. doi:.https://doi.org/10.1016/j.jocn.2015.12.037
  53. Magnus T, Beck M, Giess R, Puls I, Naumann M, Toyka KV. Disease progression in amyotrophic lateral sclerosis: predictors of survival. Muscle Nerve. 2002;25(5):709–14. doi:.https://doi.org/10.1002/mus.10090
  54. Körner S, Hendricks M, Kollewe K, Zapf A, Dengler R, Silani V, et al. Weight loss, dysphagia and supplement intake in patients with amyotrophic lateral sclerosis (ALS): impact on quality of life and therapeutic options. BMC Neurol. 2013;13(1):84. doi:.https://doi.org/10.1186/1471-2377-13-84
  55. Héritier AC, Janssens JP, Adler D, Ferfoglia RI, Genton L. Should patients with ALS gain weight during their follow-up? Nutrition. 2015;31(11-12):1368–71. doi:.https://doi.org/10.1016/j.nut.2015.06.005
  56. Genton L, Viatte V, Janssens JP, Héritier AC, Pichard C. Nutritional state, energy intakes and energy expenditure of amyotrophic lateral sclerosis (ALS) patients. Clin Nutr. 2011;30(5):553–9. doi:.https://doi.org/10.1016/j.clnu.2011.06.004
  57. Burgos R, Bretón I, Cereda E, Desport JC, Dziewas R, Genton L, et al. ESPEN guideline clinical nutrition in neurology. Clin Nutr. 2018;37(1):354–96. doi:.https://doi.org/10.1016/j.clnu.2017.09.003
  58. Bourke SC, O’Neill CL, Williams TL, Peel ET, Gibson GJ, McDermott CJ, et al. The changing landscape of non-invasive ventilation in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2012;83(4):368–9. doi:.https://doi.org/10.1136/jnnp-2012-302253
  59. Bourke SC, Tomlinson M, Williams TL, Bullock RE, Shaw PJ, Gibson GJ. Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial. Lancet Neurol. 2006;5(2):140–7. doi:.https://doi.org/10.1016/S1474-4422(05)70326-4
  60. O’Neill CL, Williams TL, Peel ET, McDermott CJ, Shaw PJ, Gibson GJ, et al. Non-invasive ventilation in motor neuron disease: an update of current UK practice. J Neurol Neurosurg Psychiatry. 2012;83(4):371–6. doi:.https://doi.org/10.1136/jnnp-2011-300480
  61. Gonzalez-Bermejo J, Morelot-Panzini C, Arnol N, Meininger V, Kraoua S, Salachas F, et al. Prognostic value of efficiently correcting nocturnal desaturations after one month of non-invasive ventilation in amyotrophic lateral sclerosis: a retrospective monocentre observational cohort study. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14(5-6):373–9. doi:.https://doi.org/10.3109/21678421.2013.776086
  62. Georges M, Attali V, Golmard JL, Morélot-Panzini C, Crevier-Buchman L, Collet JM, et al. Reduced survival in patients with ALS with upper airway obstructive events on non-invasive ventilation. J Neurol Neurosurg Psychiatry. 2016;87(10):1045–50. doi:.https://doi.org/10.1136/jnnp-2015-312606
  63. Sancho J, Servera E, Morelot-Panzini C, Salachas F, Similowski T, Gonzalez-Bermejo J. Non-invasive ventilation effectiveness and the effect of ventilatory mode on survival in ALS patients. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15(1-2):55–61. doi:.https://doi.org/10.3109/21678421.2013.855790

Most read articles by the same author(s)